Biogen IncBIIB
▲ PositiveCapitalrelevance
Raised non-GAAP EPS guidance and upcoming Phase 3 readouts, with shares below analyst target.
Impact on stocks 1
Biotech & Genomic Medicine
Biogen IncBiogen has raised its non-GAAP EPS guidance, citing expected launch growth and five upcoming Phase 3 readouts in lupus, transplant and rare diseases. The company's shares trade at $214.35, about 10% below the average analyst price target, with a 30-day return of about 8% and a one-year total shareholder return of around 54%. A Simply Wall St narrative pegs Biogen's fair value at about $227.59, suggesting the stock is 5.8% undervalued, though its price-to-earnings ratio of 37.9x is well above the 17.8x industry average and a fair ratio of 29.1x. Key risks include intensifying competition in multiple sclerosis and Alzheimer's, or underperformance of launches like LEQEMBI and ZURZUVAE.
Biogen IncRaised non-GAAP EPS guidance and upcoming Phase 3 readouts, with shares below analyst target.